Investigating Tadalafil for Female Orgasmic Disorder

Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.

What special dietary instructions should I follow?

8.Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. 9.Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA 3rd. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Other Medical Problems

Sex differences in response to tadalafil in pulmonary arterial hypertension. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. 17.Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C, Meldrum DR. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Factors associated with age at natural menopause in a multiethnic sample of midlife women.

Evidence for a difference in nitric oxide biosynthesis between healthy women and men.

What other information should I know?

These additional findings with regard to sex and estimated menopausal status provide clinicians with further information that can be used to individualize treatment for patients. The abstract was published under the title “Gender Differences in Response to PAH Therapy: 6MWD and Time to Clinical Worsening” in the International Society of Heart and Lung Transplant Annual Meeting poster session on April 25, 2013. Source of Support: HCC receives research support from National Heart, Lung, and Blood Institute grants P01 HL-103455, U01 HL-108642, R34 HL-117344, and RO1 HL-11475; the Vascular Medicine tadalafil 40mg Institute; the Institute for Transfusion Medicine; and the Hemophilia Center of Western Pennsylvania. Conflict of Interest: YR and JC are employed by United Therapeutics. 2.Humbert M, Sitbon O, Simonneau G.

Research limitations and future directions

Treatment of pulmonary arterial hypertension. ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. 27.Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS, Jones RD.

• Tadalafil is a phosphodiesterase type 5 inhibitor, acting on blood vessels.
• Its potential benefits for women focus on increased genital blood flow.
• Tadalafil is not approved by FDA for female sexual disorders.
• Some clinical trials report moderate improvements in women.
• It is sometimes combined with hormonal treatments.
• Psychological factors also influence female sexual satisfaction.
• Tadalafil’s effects on orgasm intensity are under research.
• Women with pre-existing health conditions should exercise caution.
• Dose adjustments may be necessary based on individual response.

Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.

• Tadalafil belongs to PDE5 inhibitors, aiding blood flow.
• It is sometimes called "female Viagra" in popular media.
• Tadalafil's duration of action is approximately 36 hours.
• Female users should consult healthcare providers before use.
• Tadalafil may interact with other medications like nitrates.
• Existing studies show mixed results on tadalafil’s efficacy in women.
• It may be more effective when combined with therapy.
• Not recommended for women with certain cardiovascular conditions.
• Female use of tadalafil is still experimental and investigational.

Vasc Health Risk Manag 2008;4(6):1459–1466.

How Does Cialis Work for Women?

For tadalafil-treated patients, the log-rank test did not show a consistent age-dependent effect on TCW in females (P = 0.78). In this sex-based post hoc analysis of the PHIRST study that assessed the effect of tadalafil in patients with PAH, we found a significant difference between the sexes in 6MWD change but no consistent effect of sex on TCW. This difference in 6MWD was not significant in the multivariate analysis. In the female population, a trend was found for greater improvement in 6MWD for premenopausal compared with postmenopausal women. This menopausal status trend was not present for TCW.

Study Summary

The baseline characteristics were fairly similar between males and females, with a significant difference in PAH etiology, age, and weight. The female cohort reported more atrial septal defects and was slightly younger than the male cohort. Body mass index data were missing for most patients in this study; therefore, it is unclear whether the weight difference between the sexes is physiologically significant. Female patients were grouped according to age as a surrogate marker for menopausal status; significant differences between the age groups in the distribution of PAH etiology and in 6MWD at baseline were noted. It is unclear how significant the etiology distribution was to the overall results, since the majority of each age group consisted of women with idiopathic PAH. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension.

• Tadalafil's mechanism involves relaxing blood vessel muscles.
• Effectiveness varies among women with sexual dysfunction.
• Its off-label use is more common in experimental settings.
• Tadalafil may lower blood pressure slightly in women.
• It is often studied alongside other PDE5 inhibitors.
• Duration of therapeutic effect can last over a day.
• Women should report any adverse effects to healthcare providers.
• Tadalafil may enhance sensitivity in erogenous zones.
• Overall, more research is needed for conclusive evidence.

Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression.

Why Premier Hormone Health & Wellness? Our Approach to Customized Therapy

Postmenopausal females may likely have more comorbidities than younger women, which may in part account for this trend. This trend may also be related to the low circulating levels of cardioprotective estrogen present after menopause and the estrogen-dependent mechanism of PDE-5 inhibitors.20,30 Ovariectomized mice that were treated with sildenafil did not experience the antiremodeling properties that their ovary-retaining counterparts did and, interestingly, after exogenous estrogen replacement regained benefit from sildenafil.20 On the basis of these animal data and the findings of our study, it appears that the treatment mechanism of PDE-5 inhibitors in women may require estrogen. This raises the question of whether PDE-5 inhibitors should be the optimal therapy for postmenopausal women. Limitations of this study include inconsistencies in tadalafil dosing and bosentan background therapy. In addition, information on hormone replacement therapy and hormone-based contraceptive use in this patient cohort was not available.

Statistical analysis

The assumption of menopausal status was based on age, and no actual information on patients’ menopausal status was available at the time of this study. The use of 6MWD as a primary end point and the short duration of the PHIRST study also present potential limitations. 6MWD should be viewed as an intermediate end point; further research into the impact of sex and menopausal status on the effects of PDE-5 inhibitors on mortality and morbidity is required.31,32 In conclusion, while PAH is a disorder with a known female and postmenopausal predominance, it appears that males and premenopausal females may experience greater functional improvement when treated with tadalafil than older women. No consistent effect of sex or menopause on TCW was observed. All subjects regardless of sex or age demonstrated improvement with tadalafil compared with placebo. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.

Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

• Tadalafil's mechanism targets blood vessels to promote dilation.
• It may help women with blood flow-related sexual problems.
• The drug's research status means limited official approvals.
• Female studies explore impacts on sexual satisfaction and arousal.
• Its off-label use is increasing with ongoing research.
• Tadalafil could improve genital flushing and sensitivity.
• Women with cardiac risk factors should avoid tadalafil.
• Clinical trials are testing daily versus as-needed dosing.
• User reports vary, and more evidence is necessary.

Couple sexual dysfunction is a common, but not often studied, problem.

What is Cialis?

PDE5 inhibitor efficacy is estrogen dependent in female heart disease. Pulmonary arterial hypertension in France: results from a national registry. 23.English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. 24.Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. We have previously reported that disturbance in the relational domain, as measured by SIEDY Scale 2 (exploring, as reported by the patient, menopausal symptoms, partner's medical illness interfering with sexual activity, and reduced partner desire and climax), is associated with different sexual dysfunctions, such as hypoactive sexual desire, erectile dysfunction (ED), delayed ejaculation, and psychological disturbances.

Connect with a study center

The difference in baseline 6MWD did reveal a significantly lower 6MWD for older women, which was considered when evaluating change in 6MWD. Our data indicate that males treated with tadalafil may have a clinically significant functional improvement compared with females, supporting the findings of the recently published tadalafil sex-response study.12 The authors of that study suggested that this was due to male patients having lower levels of NO and, therefore, a more robust response to the enhanced NO signaling resulting from PDE-5 inhibition.12,26 Testosterone may also play an important role given its pulmonary vasodilator action via inhibition of the L-type voltage-gated calcium channel.27 It seems likely that the observed difference in functional improvement between the sexes in this study is due to the multifactorial effects of testosterone and estrogen on the pulmonary vasculature. The difference in 6MWD between the sexes for those treated with tadalafil was statistically significant by the nonparametric Wilcoxon rank sum test. After controlling for multiple variables, including age, sex, race, etiology of PAH, WHO functional class, baseline 6MWD, and background therapy with bosentan, the observed differences in 6MWD between the sexes was no longer statistically significant. This may be due to correlation of variables in the multivariate regression model.

More common

The correlated variables compete for explaining the change in 6MWD, which may result in variables losing significance compared with the univariate analysis. Prior studies have demonstrated significant effects of cotreatment with bosentan and PDE-5 inhibitors on change in 6MWD.3,28,29 To examine these correlations, a backward model selection was performed, which demonstrated that changes in 6MWD are best explained by age, etiology of PAH, WHO functional class, and baseline 6MWD. It can be noted that sex was marginally significant in this patient cohort but that background therapy with bosentan and race were not. Our study demonstrated a trend toward more progressive worsening in postmenopausal females on the basis of change from baseline 6MWD. Interestingly, this trend was not seen for males in the same age groups, suggesting that this progressive female worsening is not necessarily due to age. As all of these symptoms could be associated with hypogonadism, we have investigated the possible relationship between androgen levels and an unhappy couple relationship.